Impact of hepatitis C virus (HCV) infection on human immunodeficiency virus (HIV) progression
| Year, reference | Location | No of coinfected patients/HIV infected alone | Duration of follow up | Outcome | OR/RR (95% CI) | Comment |
|---|---|---|---|---|---|---|
| 20017 | Canada | 78/104 | 42 months | Death | 1.59 (1.06–6.32) unadjusted | — |
| 199415 | USA | 74/438 | 84 months | Death | 0.85 (0.30–2.4) unadjusted | Selected group |
| 199920 | USA | 122/228 | 141 months | AIDS and death | No effect | 70% had AIDS |
| 200012 | Switzerland | 528/1068 | 28 months | AIDS and death | 3.45 (2.0–6.25) | Patients with well controlled HIV-1 replication |
| Clinical progression | 1.72 (1.25–2.36) | |||||
| 199321 | USA | 18/195 | — | AIDS | 0.3 (0.084–1.07) | — |
| 199958 | Canada | 22/59 | 17.2 y | AIDS and death | 2 (1.06–3.9) | Patients with progressive liver disease |
| 200175 | USA | 207 | 7 y | AIDS | 1.66 (1.1–2.51)) | Haemophiliacs |
| Death | 1.54 (1.03–2.30) | |||||
| 199876 | France | 119/119 | 3 y | AIDS and death | 1.64 (1.06–2.06) adjusted for CD4 cell count | — |
| 199577 | Italy | 214/202 | 30 months | AIDS | 0.97 (0.52–1.79) adjusted for CD4 cell count | AIDS free cohort with known seroconversion date |